Researchers find relief for chronic pain

January 22, 2008

Researchers in the Department of Medicine and Department of Neurosciences at Mount Sinai School of Medicine have discovered that chronic pain can be successfully treated with novel targeted gene therapy. In an effort to find a more effective treatment for chronic pain, researchers at Mount Sinai developed a gene therapy technique that simulates the pain-killing effect of opiate drugs.

In the new study “Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain” published in the January 22, 2008 issue of the Proceedings of the National Academy of Sciences, researchers suggest that gene therapy for pain might in the future become a treatment alternative for patients with severe chronic pain.

“Fifty million Americans suffer from chronic pain. Chronic pain patients often do not experience satisfactory pain relief from available treatments due to poor efficacy or intolerable side effects like extreme sleepiness, mental clouding, and hallucinations,” said Dr. Andreas Beutler, MD, principal investigator of the study and Assistant Professor of Medicine/ Hematology And Medical Oncology at Mount Sinai School of Medicine.

Mount Sinai researchers designed a viral vector to carry the prepro-b-endorphin gene into primary sensory neurons in order to activate opiate receptors selectively, in a rat model. The agents were delivered directly into the spinal fluid of rats via a lumbar puncture, or spinal tap with only one injection. Results showed that the rats remained symptom-free for an extended period of time.

“Our research found that treating chronic pain with Adeno-Associated Virus vector-based gene therapy allows for pain relief for more than three months after a single injection, targeting selectively the pain gate. The technique worked successfully with opioid- and non-opioid therapeutic genes,” said Dr. Beutler. “Targeted gene therapy will likely avoid the unwanted side effects associated with opioid painkillers such as morphine. Based on our findings, this targeted gene therapy via lumbar puncture appears to be a promising candidate for bench-to-bedside research that might ultimately be tested in patients with intractable chronic pain, e.g., to help patients suffering from severe pain due to advanced cancer.”

Source: The Mount Sinai Hospital

Explore further: Engineers use CRISPR technology to prevent tissue damage and resulting chronic pain

Related Stories

Zebrafish without stripes

March 14, 2017

Dowling-Degos disease is a hereditary pigmentation disorder that generally progresses harmlessly. However, some of those affected also develop severe skin inflammation. An international team of researchers under the leadership ...

Topical curcumin gel effective in treating burns and scalds

March 14, 2017

What is the effect of Topical Curcumin Gel for treating burns and scalds? In a recent research paper, published in the open access journal BioDiscovery, Dr. Madalene Heng, Clinical Professor of Dermatology at the David Geffen ...

Recommended for you

Survivors of childhood brain tumors have increased body fat

March 24, 2017

McMaster University researchers have discovered that while survivors of childhood brain tumours have a similar Body Mass Index (BMI) to healthy children with no cancer, they have more fat tissue overall, and especially around ...

Scientists unveil a giant leap for anti-aging

March 23, 2017

UNSW researchers have made a discovery that could lead to a revolutionary drug that actually reverses ageing, improves DNA repair and could even help NASA get its astronauts to Mars.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.